Neoadjuvant immunochemotherapy Clinical Trials

4 actively recruiting trials

Also known as: Neoadjuvant immunotherapy

Pipeline

Phase 2: 2Phase 3: 1

Top Sponsors

Sun Yat-sen University1
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1
Henan Cancer Hospital1
Cancer Institute and Hospital, Chinese Academy of Medical Sciences1

Indications

Cancer4
Surufatinib1
Neoadjuvant Immunochemotherapy1
Toripalimab1
Neoadjuvant Treatment1

Other4 trials

Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma

Phase 3

Neoadjuvant Immunochemotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Phase II Clinical Trial

Phase 2

Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC

Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.